A Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study M16-002 (NCT02719171)
A Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study M16-002 (NCT02719171)
This is an open-label extension (OLE) study to assess the efficacy, safety and tolerability
 of risankizumab in participants with psoriatic arthritis (PsA).
Participants who had completed all doses of study drug and the Week 24 visit of M16-002
 (NCT02719171; the lead-in study) were eligible to enroll in M16-244 (this study).
 Participants were allowed to either finish the Week 24 visit of the lead-in study and take
 the first dose of study drug for this study on the same day, or delay the start of this study
 up to 8 weeks if needed.
Inclusion Criteria:

 -  Participants who have completed all doses of study drug and Week 24 visit of the
 lead-in study.

 -  Women of childbearing potential who are sexually active, must agree to use at least
 one accepted method of contraception throughout the study, including 20 weeks after
 last dose of study drug is given.

 -  Women of childbearing potential must have a negative urine pregnancy test at Baseline
 (Week 0/V1).

 -  Participants must voluntarily sign and date an informed consent, approved by an
 Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the
 initiation of any study specific procedures.

 -  Participant is judged to be in good health as determined by the Investigator.

 Exclusion Criteria:

 -  Female participant who is pregnant, breastfeeding or is considering becoming pregnant
 during study participation, including 20 weeks after the last dose of study drug is
 given.

 -  Premature discontinuation of the study drug in the lead-in study for any reason.

 -  Use of a biologic treatment other than risankizumab since first dose of study drug in
 the lead-in study.

 -  Time elapsed is > 8 weeks since the Week 24 visit in the lead-in study.

 -  Active systemic infections during the last 2 weeks (exception: common cold) prior to
 the first dose, as assessed by the investigator.